Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Healthcare Reps at Chuikyo Call For Quality Assurance to Promote GE Use
November 1, 2011
- WT of DPJ Begins Discussion, Not Yet Known If It Covers Drug Pricing System
October 31, 2011
- Medical Benefits Rose 4.2% in FY2009, Breaking ¥30 Tril. for 1st Time
October 31, 2011
- Drug-induced Hepatitis Victims, Lawyers Petition Against Establishment of “Third Party Organization”
October 31, 2011
- MHLW Research Team Looks Into Compliance Systems, Gathering Advanced Case Studies
October 28, 2011
- CSIMC's Drug Price Committee Agrees to Review Foreign Price-Based Adjustments, Increase Downward Revising
October 28, 2011
- MHLW Varies Direction of Revision with Innovative Evaluation and Efficiency
October 28, 2011
- MHLW Calls for Package Insert Revisions for 6 Products Including Strattera
October 28, 2011
- US FDA Extends Action Date for SGLT-2 Inhibitor Dapagliflozin
October 28, 2011
- Mr Yoshimura of Astem to Be Named as Successor of Mr Matsutani: CSIMC Expert Member
October 28, 2011
- Drug-induced Hepatitis Victims Petition Against Creation of Korosho-Proposed “Third-Party Organization”
October 28, 2011
- Korosho Study Group Surveying Drug Makers’ Regulatory Compliance Systems
October 28, 2011
- Medical Benefits Rose 4.2% in FY2009, Breaking ¥30 Tril. for 1st Time
October 28, 2011
- MHLW Releases Safety Information, Calling for Proper Use of Champix
October 27, 2011
- Subcommittee to Recommend Use of Most-recent 3-Year Averages in Drug Cost Calculation
October 27, 2011
- Planning to Resume “Public-Private Dialog” by Year-End: EAD Director Kamata
October 27, 2011
- DPJ Lawmakers Opposed to TPP Criticize MHLW at Hearings
October 27, 2011
- DPJ Lawmakers Opposed to TPP Criticize Korosho at Hearings
October 26, 2011
- New Rules for Application of GCP Ordinance to Take Effect April 1, 2012
October 26, 2011
- Supreme Court Upholds Ban on Reimbursement in “Mixed Healthcare”
October 26, 2011
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…